Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 11, 2001, Pages 1783-1789

  Sakai, Takaaki ^a   Kamanna, Vaijinath S ^a   Kashyap, Moti L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apolipoproteins; Atherosclerosis; Drugs; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; CHOLESTEROL ESTER; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IODINE 125; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; TRIACYLGLYCEROL; TRITIUM;

ADULT; ARTICLE; ATHEROSCLEROSIS; CELL STRAIN HEPG2; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

EID: 0035569951     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/hq1001.096624     Document Type: Article

References (43)

1. Influence of nicotinic acid on serum cholesterol in man
2. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man
3. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid
4. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin
5. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
6. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects
7. Tolerance of nicotinic acid flushing
8. A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients
9. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans
10. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial
11. Effectiveness of once nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia
12. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
13. Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease
14. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans affairs high-density lipoprotein cholesterol intervention trial study group
15. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial
16. Basic considerations in the reversal of atherosclerosis: Significance of high density lipoproteins in stimulating reverse cholesterol transport
17. Cholesterol efflux from cultured adipose cells is mediated by LP A-I particles but not by LPA-I:A-II particles
18. Selective uptake of cholesteryl esters from high-density lipoprotein-derived LPA-I, LPA-I:A-II particles by hepatic cells in culture
19. Apolipoprotein A-I-containing lipoproteins in coronary artery disease
20. Parental history of early myocardial infraction is associated with decreased levels of lipoparticle A-I in adolescents
21. Differential electroimmunoassay of human LP-AI lipoprotein particles on ready-to-use plates
22. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate
23. Estradiol stimulates apolipoprotein A-I- but not A-II-containing particle synthesis and secretion by stimulating mRNA transcription rate in Hep G2 cells
24. Mechanistic studies of high-density lipoproteins
25. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells
26. Extended-release niacin versus gemfibrozil for treatment of low levels of high density lipoprotein cholesterol
27. International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I, B, III, comparability of apolipoprotein A-I values by use of international reference material
28. Biological factors affecting concentrations of serum LP AI lipoprotein particles in serum and determination of reference limits
29. Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2)
30. In vivo metabolism of apolipoprotein A-IV and A-I associated with high density lipoprotein in normolipidemic subjects
31. Efficient trace-labeling of proteins with iodine
32. Regulation of lipoprotein receptors on rat hepatoma in vivo
33. Hepatic catabolism of rat and human lipoproteins in rats treated with 17-α-ethinyl estradiol
34. Metabolism of iodinated high density lipoproteins in the rat
35. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin: Cholesterol acyltransferase
36. Mechanism of action of gemfibrozil on lipoprotein metabolism
37. Cubilin, the endocytic receptor for intrinsic factor-vitamin B12 complex, mediates high-density lipoprotein holoparticle endocytosis
38. The intrinsic factor-vitamin B12, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein
39. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
40. Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models
41. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis
42. In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL
43. Evidence for a new pathophysiological mechanism for coronary artery disease regression, hepatic lipase-mediated changes in LDL density